Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q4 2025 Earnings Report

Immuneering logo
$4.27 -0.30 (-6.56%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.34 +0.07 (+1.52%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q4 2025
Date
3/6/2026
Time
Before Market Opens
Conference Call Date
Friday, March 6, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Immuneering's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immuneering's Q4 2025 Press ReleasePress Release
(8-K)

Immuneering Earnings Headlines

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 11 at 7:36 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival-1036535607
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 11 at 7:36 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival-1036535607
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
September 13 at 1:00 AM  |  Porter & Company (Ad)
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference
September 10 at 7:51 AM  |  quiverquant.comQ
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
September 10 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359390/0/en/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival.html
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356257/0/en/immuneering-to-participate-in-upcoming-investor-conferences.html
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools